Axillary Hyperhidrosis (Dermatology) Drugs In Development, 2021 Report

Bekijk hier (semi) wetenschappelijke artikelen over overmatig zweten.

Moderators: Erje, Thijs

Plaats reactie
Thijs
Site Admin
Site Admin
Berichten: 2443
Lid geworden op: di 26 apr 2005, 22:45
Contacteer:

Axillary Hyperhidrosis (Dermatology) Drugs In Development, 2021 Report

Bericht door Thijs »

Axillary Hyperhidrosis (Dermatology) Drugs In Development, 2021 Report - ResearchAndMarkets.com
September 09, 2021 09:47 AM Eastern Daylight Time
DUBLIN--(BUSINESS WIRE)--The "Axillary Hyperhidrosis (Dermatology) - Drugs In Development, 2021" report has been added to ResearchAndMarkets.com's offering.

Axillary Hyperhidrosis - Drugs In Development, 2021, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights

Axillary Hyperhidrosis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 2 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).
The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)
Key Topics Covered:

Introduction

Axillary Hyperhidrosis - Overview

Axillary Hyperhidrosis - Therapeutics Development
Pipeline Overview

Pipeline by Companies
Products under Development by Companies
Axillary Hyperhidrosis - Therapeutics Assessment

Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type

Axillary Hyperhidrosis - Companies Involved in Therapeutics Development

Brickell Biotech Inc
DelNova Inc
Dermata Therapeutics Inc
Dermavant Sciences Inc
Dermira Inc
Dr. August Wolff GmbH & Co KG Arzneimittel
Medytox Inc
Revance Therapeutics Inc
Axillary Hyperhidrosis - Drug Profiles

(oxybutynin + pilocarpine)
DMT-410
glycopyrrolate
glycopyrronium tosylate
nivobotulinumtoxin A
onabotulinumtoxinA biosimilar
ReViVox -
sofpironium bromide


Featured News & Press Releases

Jun 29, 2021: Brickell Biotech announces final patient completed in first U.S. phase 3 pivotal clinical study and patient enrollment completed in second U.S. phase 3 pivotal clinical study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis
Jun 24, 2021: Brickell Biotech announces initiation of a phase 1 study of Sofpironium Bromide Gel in primary palmoplantar hyperhidrosis patients by its development partner, Kaken Pharmaceutical in Japan
Jun 01, 2021: Brickell Biotech announces publication of Japan phase 3 long-term safety and efficacy study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology
Apr 27, 2021: Brickell Biotech completes patient enrollment in U.S. phase 3 pivotal Cardigan I study of Sofpironium Bromide Gel, 15% for the treatment of primary axillary hyperhidrosis
Apr 23, 2021: Brickell Biotech reports results from U.S. phase 3 open-label, long-term safety study on chronic use of sofpironium bromide gel as a potential treatment for primary axillary hyperhidrosis
Apr 16, 2021: Brickell Biotech announces presentation of US phase 3 open-label long-term safety study results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology's 2021 VMX
Apr 15, 2021: Brickell Biotech announces publication of its HDSM-Ax patient reported outcome scale validation results in the Journal of Drugs in Dermatology
Mar 05, 2021: Brickell Biotech to host key opinion leader webinar on the hyperhidrosis market
Jan 19, 2021: Brickell Biotech announces publication of Japan pivotal phase 3 study results for Sofpironium Bromide Gel, 5% (ECCLOCK) in the Journal of Dermatology
Dec 07, 2020: Brickell Biotech doses first patient in second U.S. pivotal phase 3 clinical study
Nov 18, 2020: Brickell Biotech announces launch date for sofpironium bromide gel, 5% (ECCLOCK) in Japan by its development partner, Kaken Pharmaceutical
Oct 06, 2020: Brickell Biotech announces initiation of U.S. phase 3 program evaluating sofpironium bromide gel, 15% for the treatment of Primary Axillary Hyperhidrosis
Sep 25, 2020: Brickell Biotech announces approval of sofpironium bromide gel, 5% in Japan for treatment of primary axillary hyperhidrosis received by its development partner, Kaken Pharmaceutical
Aug 31, 2020: Brickell Biotech announces issuance of new composition of matter patent on Sofpironium Bromide by the Japanese Patent Office
Jun 15, 2020: Confirmatory phase 3 study of BBI-4000 meet primary endpoint- Announcement at the 119th Annual Meeting of the Japanese Dermatological Association and the 2020 Annual Meeting of American Academy of Dermatology

Bron: https://www.businesswire.com/news/home/ ... arkets.com
Thijs
Site Admin
Site Admin
Berichten: 2443
Lid geworden op: di 26 apr 2005, 22:45
Contacteer:

Re: Axillary Hyperhidrosis (Dermatology) Drugs In Development, 2021 Report

Bericht door Thijs »

Ja ik weet het het is Engels maar het gaat mij met name om deze nieuwe methodes waar ze dus mee bezig zijn om te ontwikkelen:

(oxybutynin + pilocarpine)
DMT-410
glycopyrrolate
glycopyrronium tosylate
nivobotulinumtoxin A
onabotulinumtoxinA biosimilar
ReViVox -
sofpironium bromide


DMT-410 was mij onbekend en google verteld hierover:

Dermata Therapeutics Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin
Published: Jul 09, 2019

SAN DIEGO, July 9, 2019 /PRNewswire/ -- Dermata Therapeutics, LLC, today announces positive results from a Phase 1 POC clinical trial of DMT410 (DMT310 + botulinum toxin (BTX)) for the treatment of primary axillary hyperhidrosis. These results provide evidence of Dermata's newly developed combination regimen, DMT400, a mechanism for topically delivering biologics into the dermis using DMT310 sponge powder.

Dermata Therapeutics, LLC

"This study provides convincing evidence that DMT310, our Spongilla lacustris powder with millions of microscopic needle-like spicules, is effective in creating channels through the stratum corneum for biologics to enter the dermis, resulting in effects similar to injections," said Gerry Proehl, President and CEO of Dermata Therapeutics, LLC.

DMT410 is a combination regimen for the treatment of skin diseases and aesthetic conditions, by first topically applying DMT310 to the skin, followed by topical application of botulinum toxin.

Study Detail: In the Phase 1 DMT410 Hyperhidrosis trial, 10 patients were enrolled at one site, in an open label, 2-arm, 4-week study. Each patient had a baseline of at least 50mg of sweat production in each axilla. Each axilla received topical application of DMT310 powder reconstituted with either hydrogen peroxide or sterile saline massaged onto the skin. After application of the DMT310 was washed off, both axillae then received topical application of BTX, reconstituted per its label, by massaging it into the same treatment area of each axilla.

Efficacy Results: The primary endpoints were the percent of patients with greater than 50% reduction in gravimetrically measured sweat production from baseline; the percent of patients with gravimetric sweat production less than 50mg; and the mean absolute change from baseline in gravimetrically measured sweat production. At Day 29, 80% of patients achieved an overall decrease in gravimetric sweat production of greater than 50%; 85% of patients achieved a gravimetric sweat production of less than 50mg; and the mean absolute change in gravimetric sweat production was -114.64mg.

DMT410 was well tolerated with only two adverse events, and only one being related to treatment. These results demonstrate DMT410's clinically meaningful effects in reducing hyperhidrosis symptoms similar to results from BOTOX® injections for hyperhidrosis.

"We are very encouraged with these results and the multiple other biologic combination therapy opportunities this presents for DMT400," stated Christopher Nardo, Ph. D, Senior VP of Development. "There are many potential benefits of using DMT310 as a dermal delivery mechanism for not only botulinum toxin but also other biologics. We believe this provides the potential for lower systemic drug exposure, greater patient acceptance due to the injection-free delivery, and the possibility to expand the use of biologics to patients with milder disease."

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists, including acne vulgaris, acne rosacea, and hyperhidrosis.

Bron: https://www.biospace.com/article/releas ... num-toxin/

Het heeft dus te maken met botox wat op de huid wordt gebracht! Dat scheelt prikken.... :ja

Revivox was mij ook onbekend. Meer hierover op: https://delnova.net/technology/revivox- ... -pipeline/
Thijs
Site Admin
Site Admin
Berichten: 2443
Lid geworden op: di 26 apr 2005, 22:45
Contacteer:

Re: Axillary Hyperhidrosis (Dermatology) Drugs In Development, 2021 Report

Bericht door Thijs »

Dit wordt zeker vervolgd en ik zal onze medisch adviseur Wim Venema om een reactie vragen! To be continued......
Thijs
Site Admin
Site Admin
Berichten: 2443
Lid geworden op: di 26 apr 2005, 22:45
Contacteer:

Re: Axillary Hyperhidrosis (Dermatology) Drugs In Development, 2021 Report

Bericht door Thijs »

Hieronder een reactie van dermatoloog Wim Venema, onze medisch adviseur, op bovenstaande berichten:
Eerst wat meer algemene woorden zodat het beter uit te leggen is wat de verschillende nieuwe in ontwikkeling zijnde medicamenten kunnen betekenen in de toekomst voor de behandeling van hyperhidrosis.

Je moet je voorstellen dat zenuwen die vanuit de hersens worden aangestuurd hun elektrische energie moeten kunnen overbrengen op de zweetklieren.

Hierbij eindigt de zenuw ter hoogte van de zweetklieren zonder dat deze een directe verbinding heeft. Er is als het ware een kloof tussen de zenuw en de zweetklieren.

Om deze kloof te overbruggen is het stofje acetylcholine erg belangrijk. Dit stofje kun je zien als een boodschapper waardoor de elektrische energie vanuit de zenuw wordt overgebracht op de zweetklieren zodat deze zweet gaan produceren.

Om het stofje acetylcholine goed aan de overkant te krijgen wordt er gebruik gemaakt van blaasjes met hierin acetylcholine. Om deze blaasjes goed te begeleiden wordt er gebruik gemaakt in het lichaam van eiwitten die als een soort touwen de blaasjes van de zenuw zijde naar de zweetklier trekken.

Als de acetylcholine eenmaal is aangekomen bij de zweetklieren kan deze binden aan receptoren (vergelijk dit met het koppelmechanisme wat je bij treinen ziet tussen wagons). Hierdoor wordt de zweetklieren aangezet.

Anticholinergica; dit zijn stofjes die het koppelen van de acetylcholine aan de zweetklieren belemmeren. Oxybutynine en Glycopyrronium waarvan in detail verschillende samenstellingen bekend zijn doen dit op efficiënte wijze. Echter bij inname van medicatie die deze stoffen bevatten zijn er vaak ook algehele bijverschijnselen. Er worden dan ook combinatiepreparaten onderzocht waarbij anticholinergica worden gecombineerd met medicamenten die de bijwerkingen tegengaan zonder de werking van het anticholinergicum te verminderen.

Ook is er de laatste jaren veel aandacht voor de ontwikkeling van meer lokale producten in gel, vloeibaar of crème ontwikkeld.

Botuline toxine; dit is een stofje wat vooral de eiwitten die de blaasjes met acetylcholine begeleiden blokkeert. Iedereen kent dit wel van de botox prikjes. De laatste jaren wordt gekeken naar de mogelijkheden van het toepassen van botox in crèmes.

In de loop van de laatste jaren zijn er meerdere botulinetoxines A op de markt gekomen met steeds iets andere moleculaire samenstelling. Mogelijk zijn er lichte verschillen in effectiviteit en duur van de effectiviteit. Deze zijn op dit moment voor de behandeling van hyperhidrosis niet zo groot dat dit enorm gaat uitmaken.

In mijn ogen is botulinetoxines B (in Nederland op dit moment niet verkrijgbaar) een goede optie als grotere gebieden met botulinetoxines moeten worden behandeld. Wat vooral een voordeel is dat het beter werkt op zweetklieren dan op spieren. Dit kan een groot voordeel zijn bij de behandeling van handen of voeten.

De opsomming van verschillende medicamenten en ontwikkelingen op de site zijn allemaal terug te voeren tot bovenstaande tekst. Er is dus veel in ontwikkeling dus blijf deze rubriek goed in de gaten houden zodat je vroegtijdig bent geïnformeerd.
Plaats reactie
  • Vergelijkbare Onderwerpen
    Reacties
    Weergaves
    Laatste bericht